Pulse Biosciences, Inc. (PLSE)

7.73 -0.09 (-1.15%) 收市：04:00PM EDT

Pulse Biosciences, Inc.

3957 Point Eden Way
Hayward, CA 94545
United States
510 906 4600
https://www.pulsebiosciences.com

版塊: Healthcare
行業: Medical Instruments & Supplies
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Robert W. Duggan	Executive Chairman	無	無	1945
Mr. Kevin P. Danahy	President & CEO	834.73k	無	1971
Mr. Darrin R. Uecker	CTO & Director	834.73k	無	1966
Mr. Mitchell E. Levinson	Chief Strategy Officer	584.57k	無	1960
Dr. Richard Nuccitelli Ph.D.	Chief Science Officer	無	無	無
Mr. Kenneth B. Stratton Esq., J.D.	General Counsel & Corporate Secretary	無	無	1969
Ms. Patty Perla	Vice President of Human Resources	無	無	無
Mr. David Danitz	Senior Vice President of Engineering	無	無	無
Dr. Gansevoort Dunnington M.D.	Chief Medical Officer	無	無	無
Dr. Niv Ad M.D.	Chief Science Officer of Cardiac Surgery	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

公司管治

截至 2024年5月1日 止，Pulse Biosciences, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：4；董事會：9；股東權利：6；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。